Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $236,539.17 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 931 shares of Natera stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total value of $236,539.17. Following the completion of the sale, the insider owned 184,069 shares of the company’s stock, valued at $46,766,410.83. The trade was a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18.
• On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The shares were sold at an average price of $202.84, for a total transaction of $291,683.92.
• On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The shares were sold at an average price of $206.16, for a total transaction of $59,992.56.

Natera Stock Down 0.7%

Shares of NTRA stock opened at $267.76 on Friday. The company has a 50 day moving average price of $246.77 and a 200-day moving average price of $222.22. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The firm has a market capitalization of $38.35 billion, a PE ratio of -164.27 and a beta of 1.51.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on NTRA shares. Wolfe Research initiated coverage on shares of Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. Royal Bank Of Canada began coverage on Natera in a report on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. Piper Sandler restated an “overweight” rating and issued a $249.00 price target on shares of Natera in a research note on Tuesday, May 12th. Sanford C. Bernstein began coverage on Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target on the stock. Finally, Barclays cut their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.83.

Hedge Funds Weigh In On Natera

Institutional investors and hedge funds have recently made changes to their positions in the business. Reflection Asset Management bought a new stake in Natera during the fourth quarter valued at approximately $29,000. Elevation Wealth Partners LLC purchased a new stake in Natera during the second quarter valued at approximately $30,000. Palladiem LLC bought a new position in Natera in the fourth quarter worth approximately $31,000. Horizon Investments LLC bought a new position in Natera in the third quarter worth approximately $32,000. Finally, International Assets Investment Management LLC boosted its stake in shares of Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.